Get the Stockscreener App
26.68
0.26%
-0.07
Spyglass Pharma Inc stock is traded at $26.68, with a volume of 83,367.
It is down -0.26% in the last 24 hours and up +0.00% over the past month.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
See More
Previous Close:
$26.75
Open:
$27.39
24h Volume:
83,367
Relative Volume:
3.41
Market Cap:
$888.91M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.41%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$26.61
$28.00
1-Week Range:
$25.50
$29.12
52-Week Range:
$24.71
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Compare SGP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
26.68 | 891.24M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spyglass Pharma Inc Stock (SGP) Latest News
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit - Bitget
1-on-1 meetings with SpyGlass Pharma at Miami biotech summit - Stock Titan
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at Citigroup - Defense World
Stifel Initiates Coverage of SpyGlass Pharma (SGP) with Buy Recommendation - Nasdaq
Spyglass Pharma (NASDAQ:SGP) Now Covered by Stifel Nicolaus - MarketBeat
Leerink Initiates SpyGlass Pharma at Outperform With $42 Price Target - marketscreener.com
Jefferies Initiates SpyGlass Pharma at Buy With $62 Price Target - marketscreener.com
Stifel initiates SpyGlass Pharma stock with buy rating on glaucoma device potential - Investing.com Canada
Spyglass Pharma (SGP) Stock Price, News & Analysis $SGP - MarketBeat
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
Spyglass Pharma (SGP) Stock Trends and Sentiment 2026 $SGP - MarketBeat
New Enterprise Associates 17, L.P. Increases Stake in SpyGlass P - GuruFocus
NEA 17 (SGP) converts preferred and buys 937,500 SpyGlass Pharma shares - Stock Titan
Latham & Watkins Advises on SpyGlass Pharma’s US$150 Million Initial Public Offering - Legal Desire Media and Insights
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - The Manila Times
SpyGlass Pharma Closes $172.5 Million IPO - marketscreener.com
SpyGlass Pharma (Nasdaq: SGP) closes $172.5M IPO at $16 per share - Stock Titan
SpyGlass Pharma closes $172.5 million IPO on NASDAQ By Investing.com - Investing.com Nigeria
SpyGlass Pharma closes $172.5 million IPO on NASDAQ - Investing.com South Africa
SpyGlass Pharma Announces Closing of Initial Public - GlobeNewswire
Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO - TipRanks
SpyGlass Pharma Raises $150 Million in Initial Public Offering - VisionMonday
SpyGlass Pharma, Inc. (SGP) Eps Diluted (TTM) - Zacks Investment Research
SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One - Smartkarma
Eye care firm SpyGlass Pharma soars 65% in trading debut - MSN
SpyGlass Pharma, Developer of Long-Acting Ocular Drug-Delivery Implants for Glaucoma and Other Chronic Eye Conditions, Files for Nasdaq Global Select Market IPO - TradingView
Eye Care Firm SpyGlass Pharma Soars 50% After $150 Million IPO - Bloomberg.com
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts - Intellectia AI
Spyglass Pharma shares surge 50% in Nasdaq debut By Investing.com - Investing.com Canada
SpyGlass PharmaSGPStock Price & News - The Motley Fool
SpyGlass Pharma raises $150 million in IPO priced at $16 per share - Investing.com Australia
SpyGlass Pharma Rings the Opening Bell - Nasdaq
SpyGlass Pharma Raises $150 Million in IPO for Eye Condition Treatments - Intellectia AI
SpyGlass Pharma raises $150 million in IPO priced at $16 per share By Investing.com - Investing.com South Africa
SpyGlass Pharma Prices $150 Million IPO - marketscreener.com
Free float of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
SpyGlass Pharma prices IPO at $16 per share, raising $150 million - Investing.com South Africa
SGP IPO NewsChronic eye condition biotech SpyGlass Pharma prices IPO at $16 midpoint - renaissancecapital.com
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO - Wilson Sonsini
SpyGlass Pharma Announces Pricing of Initial Public Offering - Yahoo Finance
SpyGlass Pharma announces pricing of IPO at $16.00 per share - marketscreener.com
Spyglass Pharma Announces Pricing Of IPO At $16.00 Per Share - TradingView
Late-stage biopharma SpyGlass Pharma to debut on Nasdaq after $150M IPO - Stock Titan
SpyGlass Pharma Debuts On Nasdaq At $16 Per Share - RTTNews
SpyGlass Pharma, Inc. Financial Statements – NASDAQ:SGP - TradingView
IPO Rating: Spyglass Pharma Inc. - Smartkarma
SpyGlass Pharma Inc (SGP): IPO Draws Demand as Med-Tech Story Gains Traction - Smartkarma
SpyGlass Pharma Sets Terms for IPO as Ophthalmology-Focused Biotech Advances Sustained-Release Platform - Smartkarma
symbol__ Stock Quote Price and Forecast - CNN
SpyGlass targets $150 million in IPO - The Pharma Letter
Spyglass Pharma Inc Stock (SGP) Financials Data
There is no financial data for Spyglass Pharma Inc (SGP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):